SER-270

About Serina Therapeutics

Serina Therapeutics is advancing a proprietary polymer platform, POZylation, to 'turn good molecules into great medicines' by extending drug half-life, reducing dosing frequency, and improving patient convenience. The company's near-term value driver is SER-252, a long-acting formulation of apomorphine for advanced Parkinson's disease, which has entered a Phase 1b registrational trial under a 505(b)(2) pathway. Backed by decades of polymer research and strategic partnerships, Serina employs a capital-efficient development model focused on enhancing known molecules to address significant unmet needs in CNS and beyond.

Therapeutic Areas